多西他赛,5氟尿嘧啶联合放疗治疗进展期食管癌.pdf

ANTICANCER RESEARCH 27 : 2597-2604 (2007) Phase I Study of Docetaxel (TXT) and 5-Fluorouracil (5-FU) with Concurrent Radiotherapy in Patients with Advanced Esophageal Cancer 1 1 1 1 JUN HIHARA , KAZUHIRO YOSHIDA , YOICHI HAMAI , MANABU EMI , YOSHIYUKI YAMAGUCHI1 and KOICHI WADASAKI2 1Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine and 2Department of Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan Abstract. This phase I study was designed to determine the patients developed grade 4 esophagitis and this dose was maximum-tolerated dose (MTD) of docetaxel (TXT) and deemed the MTD for this regimen. In the 7 assessable patients, toxicities of combining weekly administration of TXT and the overall clinical response rate was 85.7%. Conclusion: The continuous infusion of 5-fluorouracil (5-FU) with concomitant MTD of TXT in this regimen was 10 mg/m2 and the radiotherapy for advanced esophageal cancer. Patients and recommended dose of TXT was 7.5 mg/m2. Although Methods: Patients received TXT by i.v. infusion over 1 h on esophagitis was the dose-limiting and the most frequent days 1, 8, 22 and 29. They were also given 5-FU 250 toxicity, the regimen was safe and well-tolerated, and mg/m2/day by continuous infusion for 24 h on days 1-5, 8-12, demonstrated the possibility of good efficacy in patients with 15-19, 22-26